We initiate with a Strong Buy/$181 PT on Gilead Sciences, Inc. ( GILD ) . Gilead discovers, develops, and commercializes transformative therapies in the areas of HIV, viral hepatitis, oncology, and other unmet medical needs globally. Below the classicMoretus Research delivers state-of-the-art, buy-side quality equity research for serious investors seeking clarity, conviction, and alpha. Focused on U.S. public markets, Moretus applies a structured, repeatable framework to identify companies with durable busi ...